Figure 3
Figure 3. Combined pretreatment with KGF and androgen blockade significantly restore numbers of total and donor-derived naive CD4+ and CD8+ T cells in lymph node and spleen by day 35 after BMT. Lethally irradiated B6 recipients of allogeneic (BALB/c) bone marrow were left untreated (BMT Control) or pretreated with KGF, leuprolide acetate, or KGF + leuprolide acetate and analyzed for the presence of T cells in the lymph nodes and spleen at day 35 after BMT alongside unmanipulated age/sex-matched B6 control animals (non-BMT Control). Mean absolute num-bers (± SEM) of total CD4+ T cells (A,E), naive (CD45RBhighCD44low) CD4+ T cells (B,F), total CD8+ T cells (C,G), and naive (CD62LhighCD44low) CD8+ T cells (D,H) in the lymph nodes and spleen are shown. Lymph node data are represented here by pooled cells from 2 inguinal, 2 axillary, and mesenteric lymph nodes. Data are representative of 3 experiments, each with 4 mice per group; *P < .05 compared with BMT control mice; #P < .05 compared with KGF-treated BMT recipients.

Combined pretreatment with KGF and androgen blockade significantly restore numbers of total and donor-derived naive CD4+ and CD8+ T cells in lymph node and spleen by day 35 after BMT. Lethally irradiated B6 recipients of allogeneic (BALB/c) bone marrow were left untreated (BMT Control) or pretreated with KGF, leuprolide acetate, or KGF + leuprolide acetate and analyzed for the presence of T cells in the lymph nodes and spleen at day 35 after BMT alongside unmanipulated age/sex-matched B6 control animals (non-BMT Control). Mean absolute num-bers (± SEM) of total CD4+ T cells (A,E), naive (CD45RBhighCD44low) CD4+ T cells (B,F), total CD8+ T cells (C,G), and naive (CD62LhighCD44low) CD8+ T cells (D,H) in the lymph nodes and spleen are shown. Lymph node data are represented here by pooled cells from 2 inguinal, 2 axillary, and mesenteric lymph nodes. Data are representative of 3 experiments, each with 4 mice per group; *P < .05 compared with BMT control mice; #P < .05 compared with KGF-treated BMT recipients.

Close Modal

or Create an Account

Close Modal
Close Modal